The endothelial surface glycocalyx (ESG) is a dense, carbohydrate-rich mesh that coats the luminal surface of endothelial cells. It comprises glycoproteins, proteoglycans, and glycosaminoglycans (GAGs). Mechanical cues at the ESG, such as shear stress from blood flow, can be rapidly translated into intracellular biochemical signals. Dysfunction of this mechanotransduction pathway is linked to cardiovascular complications — including diabetes, stroke, sepsis, and atherosclerosis — in part because impaired signaling reduces production of the vasodilator nitric oxide (NO).
While the ESG is known to participate in mechanosignaling, the receptor-level pathways that couple specific ESG molecules to downstream signals have been incompletely defined. The study summarized here addresses that gap by combining a targeted mechanical stimulus with a quantitative readout of NO production at single-cell resolution.
The authors describe an atomic force microscopy (AFM) "force-to-signal" assay that delivers controlled, receptor-targeted mechanical inputs to a single live endothelial cell while simultaneously recording NO production via fluorescence. The AFM-based input can apply forces in the pico- to nano-newton range, enabling precise mechanical engagement of individual ESG components.
A central strength of this approach is its ability to couple a molecule-specific mechanical perturbation directly to a downstream biochemical measurement in real time. By mechanically pulling on defined ESG elements, the assay generates a direct map from receptor engagement to cellular signal, avoiding some ambiguities that arise from bulk or whole-tissue perturbations.
The assay was applied to mouse brain endothelial cells. Controlled pulling forces were applied to specific components of the ESG while fluorescent indicators tracked NO production. This single-cell, receptor-targeted experimental design allowed the investigators to determine which ESG molecules function as proximal mechanosensors and to probe downstream signaling dependencies, including ion-channel-mediated calcium entry linked to NO synthesis.
(Details such as exact AFM probe functionalization, number of cells tested, temporal resolution, or quantitative fluorescence calibration were not reported in the abstract.)
Using the AFM force-to-signal assay to selectively engage ESG constituents, the investigators found that heparan sulfate (HS) and glypican-1 operate as proximal mechanosensors. Mechanical engagement of these molecules triggered rapid NO signaling, indicating that these glycocalyx components are positioned to transduce extracellular mechanical inputs into an intracellular vasoregulatory response.
This receptor-level identification supports a model in which specific ESG molecules — not only the bulk glycocalyx — play active roles in initiating mechanotransduction events that culminate in NO production.
The researchers probed downstream ion-channel contributions to mechanically evoked NO signaling using pharmacological inhibitors. Application of SKF96365 produced a marked suppression of the mechanically induced NO response, suggesting involvement of TRP-channel-associated Ca2+ entry in the pathway linking ESG engagement to NO production.
Treatment with amiloride resulted in a smaller but still statistically significant reduction in mechanically evoked NO, indicating that additional ion transport mechanisms or channel classes may contribute to the Ca2+-dependent step(s) required for NO generation.
The pattern of pharmacological sensitivity supports a model in which glypican-1 and HS act as proximal mechanosensors that, when mechanically engaged, promote Ca2+ entry through TRP-associated pathways that in turn support rapid NO production.
By directly coupling a molecule-specific mechanical input to a quantitative fluorescent readout, the AFM force-to-signal assay provides a single-cell pathway map from receptor to downstream signal. This technique enables identification of ESG components that initiate mechanotransduction and highlights ion-channel dependencies required for NO production.
These findings have translational relevance because impairment of the ESG and its mechanosignaling capacity is associated with endothelial dysfunction in conditions such as diabetes, stroke, sepsis, and atherosclerosis. Identifying glypican-1 and HS as proximal mechanosensors and implicating TRP-channel-associated Ca2+ entry offers molecular targets that could be explored in future work aimed at restoring ESG-mediated NO signaling in disease.
The abstract provides clear findings but omits many experimental specifics in this summary format. The following details were not reported in the abstract: exact AFM probe chemistry and receptor-targeting methods; quantitative sample sizes and statistical measures; temporal kinetics of NO transients beyond the descriptor "rapid"; precise concentrations or exposure protocols for SKF96365 and amiloride; and whether multiple TRP isoforms were distinguished. These points would require consulting the full article for comprehensive methodological and quantitative information.
Funding for the work included NIH grant HL152348 and a Graduate Student Research Grant from the University of Massachusetts Amherst.
Overall, the AFM force-to-signal assay establishes a direct, minimally ambiguous link between mechanical engagement of specific ESG molecules and rapid, Ca2+-dependent NO signaling in endothelial cells, identifying glypican-1, heparan sulfate, and TRP-channel-associated Ca2+ entry as key components of the mechanotransduction pathway.